-
-
-
-
-
-
-
FDA grants RMAT designation to Prime Medicine's CGD therapy PM359
-
-
-
-
-
-
-
Goldman Sachs Reiterates Early-Stage Biotech Rating on Prime Medicine (PRME)
-
-
-
-
-
-
-
Citizens JMP Reiterates Market Outperform Rating on Prime Medicine (PRME)
-
-
-
-
-
-
-
JPMorgan Downgrades Prime Medicine (PRME) to Neutral
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Prime Medicine (PRME)
-
-
-
-
-
-
-
Prime Medicine (PRME) Files for 11M Share Offering by Selling Stockholders
-
-
-
-
-
-
-
BMO Capital Reiterates Outperform Rating on Prime Medicine (PRME)
-
443,922 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

